ACTION ALERT: What's at Stake in FDA's Hormone Attack
Thursday, January 30, 2020
The Alliance for Natural Health has been telling you for a while now about the FDA’s attack on individualized bioidentical hormone replacement therapy, particularly the threat to estriol.
To recap where we are: estriol and other bioidentical hormones have been nominated to the FDA’s Demonstrably Difficult to Compound List; items that appear on the list when it is final will no longer be able to be made at compounding pharmacies. The FDA convened a National Academies of Science, Engineering, and Medicine (NASEM) committee to study the clinical utility of treating patients with compounded bioidentical hormone replacement therapy (cBHRT); the findings of this committee will be used by the FDA to make a final decision on the fate of estriol and other compounded hormones.
What is often lost in the discussion of the data is the human impact a ban could have.
Read more about the human impact, what's a stake with the ban and how you can help HERE.